Assessment of stereoselectivity of trimethylphenylalanine analogues of δ-opioid [D-Pen2,D-Pen5]-enkephalin

Journal of Neurochemistry

Volumn 75, Issue 1, 2000, Pages 424-435

  Witt, Ken A ^a   Slate, Cheryl A ^a   Egleton, Richard D ^a   Huber, Jason D ^a   Yamamura, Henry I ^a   Hruby, Victor J ^a   Davis, Thomas P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Opioid receptor; D Pen,D Pen2,5 Enkephalin; Analgesia; Stereoselectivity; Trimethylphenyl alanine

Indexed keywords

DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO PHENYLALANINE 5 DEXTRO PHENYLALANINE]; OPIATE PEPTIDE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONFORMATION; CONTROLLED STUDY; FEMALE; NONHUMAN; OPTICAL ROTATION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STEREOCHEMISTRY;

ALANINE; ANALGESIA; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CATTLE; ENDOTHELIUM, VASCULAR; ENKEPHALIN, D-PENICILLAMINE (2,5)-; FEMALE; METHYLATION; MOLECULAR CONFORMATION; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; BOVINAE; MAMMALIA;

EID: 0034126585     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0750424.x     Document Type: Article

References (83)

1. Abbruscato T. J., Williams S. A., Misicka A., Lipkowski A. W., Hruby V. J., and Davis T. P. (1996) Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276, 1049-1057.
2. Alyautdin R. N., Petrov V. E., Langer K., Berthold A., Kharkevich D. A., and Kreuter J. (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyano-acrylate nanoparticles. Pharm. Res. 14, 325-328.
3. Audus K. L. and Borchardt R. T. (1986) Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm. Res. 3, 81-87.
4. Audus K. L. and Borchardt R. T. (1987) Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. NY Acad. Sci. 507, 9-18.
5. Banks W. A. and Kastin A. J. (1985) Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res. Bull. 15, 287-292.
6. Banks W. A., Schally A. V., Barrera C. M., Fasold M. B., Durham D. A., Csernus V. J., Groot K., and Kastin A. J. (1990) Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA 87, 6762-6766.
7. Bartosz-Bechowski H., Davis P., Zalewska T., Slaninova J., Porreca F., Yamamura H. I., and Hruby V. J. (1994) Cyclic enkephalin analogs with exceptional potency at peripheral delta opioid receptors. J. Med. Chem. 7, 146-150.
8. Begley D. J. (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48, 136-146.
9. Bolton A. E. (1986) Comparative methods for the radiolabeling of peptides. Methods Enzymol. 124, 18-29.
10. Bondi A. (1964) Van der Waals volumes and radii. J. Phys. Chem. 68, 441-451.
11. Brocks D. R. and Fakhreddin J. (1995) Stereochemical aspects of pharmacotherapy. Pharmacotherapy 15, 551-564.
12. Brownson E. A., Abbruscato T. J., Gillespie T. J., Hruby V. J., and Davis T. P. (1994) Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 270, 675-680.
13. Burton P. S., Conradi R. A., Ho N. F., Hilgers A. R., and Borchardt R. T. (1996) How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85, 1336-1340.
14. Chen C. and Pollack G. M. (1998) Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J. Pharmacol. Exp. Ther. 287, 545-552.
15. Chen C. and Pollack G. M. (1999) Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm. Res. 16, 296-301.
16. Collins J. M. and Dedrick R. L. (1983) Distributed model for drug delivery to CSF and brain tissue. Am. J. Physiol. 245, R303-R310.
17. Conradi R. A., Hilgers A. R., Ho N. F., and Burton P. S. (1992) The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9, 435-439.
18. Davis T. P., Abbruscato T. J., Brownson E., and Hruby V. J. (1995) Conformationally constrained peptide drugs targeted at the blood-brain barrier. NIDA Res. Monogr. 154, 47-60.
19. Davson H., Kleeman C. R., and Levin E. (1961) Blood-brain barrier and extracellular space. J. Physiol. (Lond.) 159, 67P-68P.
20. Dietzmann K., Bossanyi P. V., and Franke D. S. (1994) Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma (German). Zentralbl. Pathol. 140, 149-153.
21. Egleton R. D. and Davis T. P. (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18, 1431-1439.
22. 2,5]enkephalin across the blood-brain barrier involves transcytosis. J. Pharm. Sci. 88, 392-397.
23. Egleton R. D., Abbruscato T. J., Thomas S. A., and Davis T. P. (1998) Transport of opioid peptides into the central nervous system. J. Pharm. Sci. 87, 1433-1439.
24. Erchegyi J., Kastin A. J., Zadina J. E., and Qui X.-D. (1991) Isolation of a heptapeptide Val-Val-Tyr-Pro-Trp-Thr-G1n (valorphin) and some opiate activity. Int. J. Pept. Protein Res. 39, 477-488.
25. Fisher J. F., Harrison A. W., Bundy G. L., Wilkinson K. F., Rush B. D., and Ruwart M. J. (1991) Peptide to glycopeptide: glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J. Med. Chem. 34, 3140-3143.
26. Fontaine M., Elmquist W. F., and Miller D. W. (1996) Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 59, 1521-1531.
27. Foxwell B. M., Mackie A., Ling V., and Ryffel B. (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol. Pharmacol. 36, 543-546.
28. Frederickson R. C. A., Smithwick E. L., Shuman R., and Bemis K. G. (1981) Metkephamid, a systemically active analog of methionine enkephalin with potent delta-receptor activity. Science 211, 603-605.
29. Galligan J. J., Mosberg H. I., Hurst R., Hruby V. J., and Burks T. F. (1984) Cerebral δ opioid receptors mediate analgesia but not intestinal motility effects of intracerebroventricularly administered opioids. J. Pharmacol. Exp. Ther. 229, 641-648.
30. Gentry C. L., Egelton R. D., Gillespie T. J., Abbruscato T. J., Bechowski H. B., Hruby V. J., and Davis T. P. (1999) The effects of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides 20, 1229-1238.
31. Golden P. L. and Pardridge W. M. (1999) P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res. 20, 143-146.
32. Granholm A. C., Albeck D., Backman C., Curtis M., Ebendal T., Friden P., Henry M., Hoffer B., Kordower J., Rose G. M., Soderstrom S., and Bartus R. T. (1998) A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review. Rev. Neurosci. 9, 31-55.
33. Gysin B. F. (1973) The preparation of Merrifield-resins through total esterification with cesium salts. Helv. Chem. Acta 34, 595-598.
34. 5]-enkephalin (DPDPE). Int. J. Pept. Protein Res. 36, 139-146.
35. Hambrook J. M., Morgan B. A., Rance M. J., and Smith C. F. (1976) Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature 26, 782-783.
36. 5]enkephalin. J. Med. Chem. 35, 684-687.
37. Heyl D. L., Omnaas J. R., Sobczyk-Kojiro K., Medzihradsky F., Smith C. B., and Mosberg H. I. (1991) Opioid receptor affinity and selectivity effects of second residue and carboxy terminal residue variation in a cyclic disulfide-containing opioid tetrapeptide. Int. J. Pept. Protein Res. 37, 224-229.
38. 5]-enkephalin (DPDPE) analgesia in mice. NIDA Res. Monogr. 75, 442-445.
39. Hruby V. J. (1982) Conformational restrictions of biologically active peptides via side chain groups. Life Sci. 31, 189-199.
40. 5]enkephalin in aqueous solution determined by NMR and energy minimization calculations. J. Am. Chem. Soc. 110, 3351-3359.
41. 5]enkephalin. J. Med. Chem. 34, 1823-1830.
42. Hruby V. J., Kazmierski W., Kawasaki A. M., and Matsunaga T. O. (1991b) Peptide pharmaceuticals, in Synthetic Chemistry and the Design of Peptide-Based Drugs (Ward D., ed), pp. 135-184. Open University Press, Celtic Court, Buckingham.
43. Hruby V. J., Yamamura H. I., and Porreca F. (1995) Molecular organization of receptors. Efficacy, agonists, and antagonists. Ann. NY Acad. Sci. 10, 7-22.
44. Hruby V. J., Barosz-Bechowski H., Davis P., Slaninova J., Zalewska T., Stropova D., Porreca F., and Yamamura H. I. (1997) Cyclic enkephalin analogues with exceptional potency and selectivity for δ-opioid receptors. J. Med. Chem. 40, 3957-3962.
45. Hughes J., Smith T. W., Kosterlitx H. W., Forthergill L. A., Morgan B. A., and Morris H. R. (1975) Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258, 577-579.
46. Hui K. S., Wang Y. J., and Lajtha A. (1983) Purification and characterization of an enkephalin aminopeptidase from rat brain membranes. Biochemistry 1, 1062-1067.
47. Kaiser E., Colescott R. L., Bossinger C. D., and Cook P. I. (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34, 595-598.
48. Kazmierski W., Wire W. S., Lui G. K., Knapp R. J., Shook J. E., Burks T. F., Yamamura H. I., and Hruby V. J. (1988) Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. J. Med. Chem. 31, 2170-2177.
49. Knapp R. J., Kazmierski W., Hruby V. J., and Yamamura H. I. (1989) Structural characteristics of two highly selective opioid peptides. Bioassays 10, 58-61.
50. 5]enkephalin: a selective high affinity radioligand for delta opioid receptors with exceptional specific activity. J. Pharmacol. Exp. Ther. 258, 1077-1083.
51. Letrent S. P., Polli J. W., Humphreys J. E., Pollack G. M., Brouwer K. R., and Brouwer K. L. (1999) P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 15, 951-957.
52. Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J Biol. Chem. 193, 265-275.
53. Lum B. L. and Gosland M. P. (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 9, 319-336.
54. Misicka A. and Hruby V. J. (1994) Optimization of disulfide bond formation. Pol. J. Chem. 68, 893-899.
55. Mosberg H. I., Hurst R., Hruby V. J., Gee K., Yamamura H. I., Galligan J. J., and Burks T. F. (1983) Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc. Natl. Acad. Sci. USA 80, 5871-5874.
56. Nikiforovich G. V., Hruby V. J., Prakash O., and Gehrig C. A. (1991) Topographical requirements for delta-selective opioid peptides. Biopolymers 31, 941-955.
57. Ogihara T., Tamai I., Takanaga H., Sai Y., and Tsuji A. (1996) Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharm. Res. 13, 1828-1832.
58. Okuda T., Tsuchiya N., Wakita K., Hatsuoka K., Koga Y., Ueda S., and Kaetsu I. (1996) Prolonged antinociceptive effect after epidural injection of polyethylene glycol-morphine composites in rats. Masui 45, 571-575.
59. Pardridge W. M., Buciak J. L., and Friden P. M. (1991) Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259, 66-70.
60. Pardridge W. M., Kang Y. S., Yang J., and Buciak J. L. (1995) Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J. Pharm. Sci. 84, 943-948.
61. Patel A., Smith H. J., and Sewell R. D. (1993) Inhibitors of enkephalin-degrading enzymes as potential therapeutic agents. Prog. Med. Chem. 30, 327-378.
62. Polt R., Porreca F., Szabo L. Z., Bilsky E. J., Davis P., Abbruscato T. J., Davis T. P., Hovath R., Yamamura H. I., and Hruby V. J. (1994) Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. USA 91, 7114-7118.
63. 14C-mannitol using the rat in situ brain perfusion technique. Dev. Brain Res. 87, 69-76.
64. Qian X., Liao S., Stropova D., Yamamura H. I., and Hruby V. J. (1996a) Novel scaffolds for non-peptide mimetics of delta opioid receptor agonist based on peptide leads. Regul. Pept. 27, 79-82.
65. Qian X., Shenderovich M. D., Kover K. E., Davis P., Hovath R., Zalewska T., Yamamura H. I., Porreca F., and Hruby V. J. (1996b) Probing the stereochemical requirements for receptor recognition of opioid agonists through topographical modifications in position 1. J. Am. Chem. Soc. 118, 7280-7290.
66. Quock R. M., Burkey T. H., Varga E., Hosohata Y., Hosohata K., Cowell S. M., Slate C. A., Ehlert F. J., Roeske W. R., and Yamamura H. I. (1999) The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev. 51, 503-532.
67. Schetz J. A., Mayr C. A., Taylor J. E., Rosenblatt M., Chorev M., and Davis T. P. (1995) Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat. J. Pharmacol. Exp. Ther. 274, 1456-1462.
68. Schinkel A. H., Wagenaar E., Mol C. A., and van Deemter L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1, 2517-2524.
69. Shook J. E., Pelton J. T., Hruby V. J., and Burks T. F. (1987) Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J. Pharmacol. Exp. Ther. 243, 492-500.
70. Tallarida R. J. and Murry R. B. (1987) Manual of Pharmacology Calculations with Computer Programs. Springer-Verlag, New York.
71. Tamai I., Sai Y., Kobayashi H., Kamata M., Wakamiya T., and Tsuji A. (1997) Structure-internalization relationships for absorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280, 1235-1240.
72. 2,5]enkephalin into the central nervous system: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 280, 1235-1240.
73. 5]enkephalin (DPDPE) analogues with increased affinity and selectivity for delta opioid receptors. J. Med. Chem. 33, 249-253.
74. 5]enkephalin with δ opioid receptor selectivity. J. Med. Chem. 35, 2384-2391.
75. Triguero D., Buciak J., and Pardridge W. M. (1990) Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54, 1882-1888.
76. Tseng L. F. (1986) Stereoselective effect of beta-endorphin on the production of analgesia and the spinal release of met-enkephalin in rats. J. Pharmacol. Exp. Ther. 239, 160-165.
77. 4]deltorphin with δ-opioid receptor subtypes in vivo. Eur. J. Pharmacol. 252, 133-137.
78. 5]enkephalin and two halogenated analogs after intravenous administration. J. Pharmacol. Exp. Ther. 259, 1308-1316.
79. 5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263, 1308-1316.
80. 5]enkephalin opioid analogs. J. Pharmacol. Exp. Ther. 266, 1649-1655.
81. 2,5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66, 1289-1299.
82. Xiang L., Wu H., and Hruby V. J. (1995) Stereoselective synthesis of all individual isomers of β-methyl-2′,6′-dimethylphenylalanine. Tetrahedron Asym. 6, 84-86.
83. Zlokovic B. V., Banks W. A., Kadi H. E., Erchegyi J., Mackic J. B., McComb J. G., and Kastin A. J. (1992) Transport, uptake and metabolism of blood-borne vasopressin by the blood-brain barrier. Brain Res. 590, 213-218.